SCHEMBL4603742

SCHEMBL4603742

CCCN(CCC)c1ccccc1OCc1ccc(NC(=O)CC)c(C(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
PKM P14618 2/20 0.47
ALDH1A1 P00352 5/20 0.44
HSD17B10 Q99714 2/20 0.44
DHODH Q02127 1/20 0.44
DVL1 O14640 1/20 0.42
GAA P10253 1/20 0.41
LTC4S Q16873 1/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
FOLH1 Q04609 1/20 0.40
POLB P06746 1/20 0.39
G6PD P11413 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
EGFR P00533 2/20 0.39
ERBB4 Q15303 2/20 0.39
METAP2 P50579 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4603647 0.84 KDM4E (0.46) KDM4EPKMALDH1A1HSD17B10DHODH
SCHEMBL4605334 0.81 KDM4E (0.52) KDM4EPKMALDH1A1HSD17B10DHODH
SCHEMBL4603804 0.80 KDM4E (0.46) KDM4EPKMALDH1A1HSD17B10DHODH
SCHEMBL4605129 0.80 DVL1 (0.51) KDM4EPKMALDH1A1DHODHDVL1
SCHEMBL4606969 0.80 DVL1 (0.56) KDM4EPKMALDH1A1HSD17B10DHODH
SCHEMBL4605839 0.79 RXRA (0.57) KDM4EPKMALDH1A1HSD17B10DVL1
SCHEMBL4604536 0.79 RXRA (0.57) KDM4EPKMALDH1A1HSD17B10DHODH
SCHEMBL4606153 0.78 NPSR1 (0.48) PKMALDH1A1GAANPSR1POLB
SCHEMBL4605960 0.77 GAA (0.47) KDM4EPKMALDH1A1HSD17B10GAA
SCHEMBL1824710 0.76 KDM4E (0.48) KDM4EPKMALDH1A1HSD17B10DVL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 KDM4E 2898/4885PKM 2002/4885ALDH1A1 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.